Expression and clinical significance of BCAR4 in glioma tissues
WANG Zhifeng
WANG Longlong
LI Guojing
DUAN Shibo
XI Yanguo
Abstract：Objective To explore the expression and clinical significance of long chain non-coding RNA breast cancer anti-estrogen resistance 4(BCAR4)in glioma tissues.Methods Real-time quantitative PCR was used to detect the expression level of BCAR4 in 60 glioma tissues and adjacent normal tissues.Kaplan-Meier test was used to analyze the relationship between BCAR4 expression and overall survival(OS)of glioma patients.Cox proportional risk model was used to analyze the risk factors for prognosis.Results Compared with adjacent tissues,the expression level of BCAR4 in glioma tissues was significantly increased(2.25±0.46 vs.1.01±0.69,P<0.05).The expression of BCAR4 in glioma tissues was related to the WHO grading and tumor size of patients(P<0.05).Based on follow-up data,the OS curve of glioma patients was plotted.The median OS of patients with BCAR4 low expression was 38 months,which was better than 19 months of patients with BCAR4 high expression(P<0.05).Multivariate analysis showed that BCAR4 expression was a risk factor affecting the prognosis of glioma patients(HR=2.651,95%CI:1.516-4.635,P<0.001).Conclusion The expression of BCAR4 is elevated in glioma and can serve as a potential molecular marker for the diagnosis and prognosis prediction of glioma patients.
Keywords：GliomaLong chain non-coding RNABreast cancer anti-estrogen resistance 4Clinical significance
Publication Date：2023-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1026-1029 )